Peramivir: An intravenous neuraminidase inhibitor

Milena M. Mclaughlin, Erik W. Skoglund, Michael G. Ison*

*Corresponding author for this work

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Introduction: Peramivir (BCX-1812, RWJ-270201) is a highly selective inhibitor of influenza A and B neuraminidase that has recently been approved in the USA by the FDA to treat acute, uncomplicated influenza in adults.Areas covered: This review examines the discovery and development of peramavir as well as its role in the treatment of influenza. Peramivir is currently the only FDA-approved anti-influenza agent that can be given as an intravenous injection, granting it a unique role in therapy with the potential to improve adherence and outcomes in patients who are unable to tolerate oral agents. In vitro, animal, human and safety data are presented as well as information regarding special populations, resistance and drug approval.Expert opinion: Clinical trial data support the use of peramivir to relieve influenza symptoms in acute, uncomplicated influenza, with improvements over placebo similar to those of other approved anti-influenza treatments. The ability to give a one-time injectable dose offers improved adherence over currently available oral regimens. While not approved for hospitalized patients, available data suggest that multiple dose peramivir may also have a role in treatment of severally ill, hospitalized patients. Supportive data for the use of peramivir in special patient populations such as pediatrics and those especially at-risk to develop severe influenza symptoms are promising; however, they require further study.

Original languageEnglish (US)
Pages (from-to)1889-1900
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number12
DOIs
StatePublished - Aug 1 2015

Fingerprint

Neuraminidase
Human Influenza
Drug Approval
Expert Testimony
Therapeutics
peramivir
Intravenous Injections
Population
Placebos
Clinical Trials
Pediatrics
Safety
Injections

Keywords

  • influenza
  • neuraminidase inhibitor
  • oseltamivir
  • peramivir
  • zanamivir

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Mclaughlin, Milena M. ; Skoglund, Erik W. ; Ison, Michael G. / Peramivir : An intravenous neuraminidase inhibitor. In: Expert Opinion on Pharmacotherapy. 2015 ; Vol. 16, No. 12. pp. 1889-1900.
@article{c9973b858492497dbd83ebd912489e38,
title = "Peramivir: An intravenous neuraminidase inhibitor",
abstract = "Introduction: Peramivir (BCX-1812, RWJ-270201) is a highly selective inhibitor of influenza A and B neuraminidase that has recently been approved in the USA by the FDA to treat acute, uncomplicated influenza in adults.Areas covered: This review examines the discovery and development of peramavir as well as its role in the treatment of influenza. Peramivir is currently the only FDA-approved anti-influenza agent that can be given as an intravenous injection, granting it a unique role in therapy with the potential to improve adherence and outcomes in patients who are unable to tolerate oral agents. In vitro, animal, human and safety data are presented as well as information regarding special populations, resistance and drug approval.Expert opinion: Clinical trial data support the use of peramivir to relieve influenza symptoms in acute, uncomplicated influenza, with improvements over placebo similar to those of other approved anti-influenza treatments. The ability to give a one-time injectable dose offers improved adherence over currently available oral regimens. While not approved for hospitalized patients, available data suggest that multiple dose peramivir may also have a role in treatment of severally ill, hospitalized patients. Supportive data for the use of peramivir in special patient populations such as pediatrics and those especially at-risk to develop severe influenza symptoms are promising; however, they require further study.",
keywords = "influenza, neuraminidase inhibitor, oseltamivir, peramivir, zanamivir",
author = "Mclaughlin, {Milena M.} and Skoglund, {Erik W.} and Ison, {Michael G.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1517/14656566.2015.1066336",
language = "English (US)",
volume = "16",
pages = "1889--1900",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "12",

}

Peramivir : An intravenous neuraminidase inhibitor. / Mclaughlin, Milena M.; Skoglund, Erik W.; Ison, Michael G.

In: Expert Opinion on Pharmacotherapy, Vol. 16, No. 12, 01.08.2015, p. 1889-1900.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Peramivir

T2 - An intravenous neuraminidase inhibitor

AU - Mclaughlin, Milena M.

AU - Skoglund, Erik W.

AU - Ison, Michael G.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Introduction: Peramivir (BCX-1812, RWJ-270201) is a highly selective inhibitor of influenza A and B neuraminidase that has recently been approved in the USA by the FDA to treat acute, uncomplicated influenza in adults.Areas covered: This review examines the discovery and development of peramavir as well as its role in the treatment of influenza. Peramivir is currently the only FDA-approved anti-influenza agent that can be given as an intravenous injection, granting it a unique role in therapy with the potential to improve adherence and outcomes in patients who are unable to tolerate oral agents. In vitro, animal, human and safety data are presented as well as information regarding special populations, resistance and drug approval.Expert opinion: Clinical trial data support the use of peramivir to relieve influenza symptoms in acute, uncomplicated influenza, with improvements over placebo similar to those of other approved anti-influenza treatments. The ability to give a one-time injectable dose offers improved adherence over currently available oral regimens. While not approved for hospitalized patients, available data suggest that multiple dose peramivir may also have a role in treatment of severally ill, hospitalized patients. Supportive data for the use of peramivir in special patient populations such as pediatrics and those especially at-risk to develop severe influenza symptoms are promising; however, they require further study.

AB - Introduction: Peramivir (BCX-1812, RWJ-270201) is a highly selective inhibitor of influenza A and B neuraminidase that has recently been approved in the USA by the FDA to treat acute, uncomplicated influenza in adults.Areas covered: This review examines the discovery and development of peramavir as well as its role in the treatment of influenza. Peramivir is currently the only FDA-approved anti-influenza agent that can be given as an intravenous injection, granting it a unique role in therapy with the potential to improve adherence and outcomes in patients who are unable to tolerate oral agents. In vitro, animal, human and safety data are presented as well as information regarding special populations, resistance and drug approval.Expert opinion: Clinical trial data support the use of peramivir to relieve influenza symptoms in acute, uncomplicated influenza, with improvements over placebo similar to those of other approved anti-influenza treatments. The ability to give a one-time injectable dose offers improved adherence over currently available oral regimens. While not approved for hospitalized patients, available data suggest that multiple dose peramivir may also have a role in treatment of severally ill, hospitalized patients. Supportive data for the use of peramivir in special patient populations such as pediatrics and those especially at-risk to develop severe influenza symptoms are promising; however, they require further study.

KW - influenza

KW - neuraminidase inhibitor

KW - oseltamivir

KW - peramivir

KW - zanamivir

UR - http://www.scopus.com/inward/record.url?scp=84937710577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937710577&partnerID=8YFLogxK

U2 - 10.1517/14656566.2015.1066336

DO - 10.1517/14656566.2015.1066336

M3 - Article

C2 - 26153242

AN - SCOPUS:84937710577

VL - 16

SP - 1889

EP - 1900

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 12

ER -